Pharmacogenetic predictors of the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode
- Authors: Ivashchenko D.V.1,2, Buromskaya N.I3, Shimanov P.V3, Deich R.V3, Dorina I.V3, Nastovich M.I3, Akmalova K.A1, Kachanova A.A1, Grishina E.A1, Savchenko L.M1, Shevchenko Y.S1, Sychev D.A1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Penza Institute for Advanced Training of Doctors - Branch of Russian Medical Academy of Continuous Professional Education
- G.E. Sukharev Scientific and Practical Center for Mental Health of Children and Adolescents
- Issue: Vol 28, No 11 (2021)
- Pages: 77-83
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313280
- DOI: https://doi.org/10.18565/pharmateca.2021.11.77-83
- ID: 313280
Cite item
Abstract
Keywords
Full Text
About the authors
Dmitry V. Ivashchenko
Russian Medical Academy of Continuous Professional Education; Penza Institute for Advanced Training of Doctors - Branch of Russian Medical Academy of Continuous Professional Education
Email: dvi1991@yandex.ru
Senior Researcher, Research Institute for Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education ; Associate Professor at the Department of Psychiatry, Psychiatry-Narcology and Psychotherapy, Penza Institute for Advanced Medical Education - Branch Campus of the Russian Medical Academy of Continuous Professional Education Moscow, Russia
N. I Buromskaya
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
P. V Shimanov
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
R. V Deich
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
I. V Dorina
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
M. I Nastovich
G.E. Sukharev Scientific and Practical Center for Mental Health of Children and AdolescentsMoscow, Russia
K. A Akmalova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
A. A Kachanova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
E. A Grishina
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
L. M Savchenko
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
Yu. S Shevchenko
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
D. A Sychev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
References
- Abidi S. Psychosis in children andyouth: focus on early-onset schizophrenia. Pediatr Rev. 2013;34(7):296-305. doi: 10.1542/pir.34-7-296.
- Haddad P.M., Correll C.U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303-18. doi: 10.1177/2045125318781475.
- Kahn R.S., Fleischhacker W.W., Boter H., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-97. doi: 10.1016/S0140-6736(08)60486-9.
- Chan V. Schizophrenia and Psychosis: Diagnosis, Current Research Trends, and Model Treatment Approaches with Implications for Transitional Age Youth. Child Adolesc Psychiatr Clin N Am. 2017;26(2):341-66. Doi: 10.1016/j. chc.2016.12.014.
- Martinuzzi E., Barbosa S., Daoudlarian D., et al. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatr. 2019;9(1):20. Doi: 10.1038/ s41398-018-0366-5.
- Cacabelos R., Hashimoto R., Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatr Clin Neurosci. 2011;65(1):3-doi: 10.1111/j.1440-1819.2010.02168.x.
- Gründer G., Heinze M., Cordes J., et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet. Psychiatr. 2016;3(8):717-29. doi: 10.1016/S2215-0366(16)00085-7.
- Maayan L., Correll C.U. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517-35. doi: 10.1089/cap.2011.0015.
- Schneider C., Taylor D., Zalsman G., et al. Antipsychotics use in children and adolescents: An on-going challenge in clinical practice. J Psychopharmacol. 2014;28(7):615-23. doi: 10.1177/0269881114533599.
- Datta S.S., Kumar A., Wright S.D., et al. Evidence base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull. 2014;40(2):252-54.
- Minjon L., van den Ban E., de Jong E., et al. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics. J Child Adolesc Psychopharmacol. 2019;29(2):124-32. doi: 10.1089/cap.2018.0139.
- Bai Y., Liu T., Xu A., et al. Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Expert Opin Drug Saf. 2019;18(8):703-17. doi: 10.1080/14740338.2019.1632832.
- Stafford M.R., Mayo-Wilson E., Loucas C.E., et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and metaanalysis. PLoS One. 2015;10(2):e0117166. doi: 10.1371/journal.pone.0117166.
- Bioque M., Llerena A., Cabrera B., et al. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. Int J Neuropsychopharmacol. 2016;19(4):121. doi: 10.1093/ijnp/pyv121.
- van Westrhenen R., Aitchison K.J., Ingelman-Sundberg M., et al. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Front. Psychiatr. 2020;11:94. Doi: 10.3389/ fpsyt.2020.00094.
- Wehry A.M., Ramsey L., Dulemba S.E., et al. Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. Curr Probl Pediatr Adolesc. Health Care. 2018;48(2):40-9. doi: 10.1016/j.cppeds.2017.12.003.
- Maruf A.A., Stein K., Arnold P.D., et al. CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. J Child Adolesc Psychopharmacol. 2021;31(1):33-45. doi: 10.1089/cap.2020.0093.
- Иващенко Д.В., Буромская Н.И., Шиманов П.В. и др. Полиморфный вариант HTR2A rs6313 ассоциирован с нежелательными реакциями на антипсихотики у подростков с острым психотическим эпизодом. Фарматека. 2021;28(9):45-51
- Иващенко Д.В., Петунова Ю.Л. и др. Полиморфные варианты генов ANKS1B rs7968606 (C>T) и ZNF804A rs1344706 (G>T) не ассоциированы с эффективностью и безопасностью применения антипсихотиков у подростков с острым психотическим эпизодом. Фарматека. 2021;28(9):28-33
- Иващенко Д.В., Иванюта М.В., Буромская Н.И. и др. Носительство полиморфного варианта COMT rs4680 ассоциировано с лучшей переносимостью антипсихотиков у подростков с острым психотическим эпизодом: проспективное обсервационное клиническое исследование. Фарматека. 2021;28(3):62-7
- Иващенко Д.В., Федина Л.В., Юделевич Д.А. и др. Полиморфные варианты генов рецепторов дофамина DRD2, DRD3 и DRD4 ассоциированы с ранней эффективностью и безопасностью антипсихотиков у подростков с острым психотическим эпизодом. Клиническая фармакология и терапия. 2021;30(2):75-80
- Ivashchenko D.V., Khoang S.Z., Makhmudova B.V., et al. Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. Drug Metab Pers Ther. 2020;4(35):20200102. doi: 10.1515/dmpt-2020-0102.
- Jallaq S.A., Verba M., Strawn J.R., et al. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. J Child Adolesc Psychopharmacol. 2021;31(1):56-62. doi: 10.1089/cap.2020.0058.
- Oshikoya K.A., Neely K.M., Carroll R.J., et al. CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res. 2019;85(5):602-6. doi: 10.1038/s41390-019-0305-z.
- Youngster I., Zachor D.A., Gabis L.V., et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study Dev Med Child Neurol. 2014;56(10):990-94. Doi: 10.1111/ dmcn.12470.
- Gradinaru R., Andreescu N., Nussbaum L., et al. Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. Ir J Med Sci. 2019;188(4):1417-doi: 10.1007/s11845-019-01985-x.
- Brown J.T., Campo-Soria C., Bishop J.R. Current strategies for predicting side effects from second generation antipsychotics in youth. Expert Opin Drug Metab Toxicol. 2021;17(6):655-64. doi: 10.1080/17425255.2021.1922668.